Roche Acquires Poseida Therapeutics

AstraZeneca Acquires Neogene Therapeutics

November 29, 2022

Biotechnology

AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.

Roche Acquires Good Therapeutics to Gain PD-1-regulated IL-2 Program

September 7, 2022

Biotechnology

Roche has entered into a definitive merger agreement to acquire Good Therapeutics, a Seattle-based privately held biopharmaceutical company, for an upfront $250 million plus milestone payments. The deal gives Roche rights to Good Therapeutics' conditionally active PD-1-regulated IL-2 program and an exclusive right to the platform for developing PD-1-regulated IL-2 receptor agonists; the transaction is expected to close in Q3 2022 subject to HSR clearance.

Merck & Co. Acquires Cidara Therapeutics

January 8, 2026

Biotechnology

Merck & Co., through subsidiary Merck Sharp & Dohme LLC, completed a cash tender offer to acquire Cidara Therapeutics, Inc. for $221.50 per share, making Cidara a wholly owned subsidiary. The acquisition adds Cidara's long-acting antiviral candidate CD388 to Merck's respiratory portfolio and is being accounted for as an asset acquisition.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.

Vertex Pharmaceuticals Acquires Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $65 per share (approximately $4.9 billion) in cash. The acquisition adds Alpine’s lead candidate povetacicept (ALPN‑303) and protein-engineering/immunotherapy capabilities to Vertex’s pipeline and is expected to close in Q2 2024, subject to customary conditions.

Pfizer Acquires Seagen for $43 Billion

December 14, 2023

Biotechnology

Pfizer completed the acquisition of Seagen, acquiring all outstanding Seagen common stock for $229 per share in cash in a transaction valued at approximately $43 billion. The deal adds Seagen's ADC technology, four in-line oncology medicines and a large early-stage pipeline to Pfizer's oncology portfolio, expanding Pfizer's capabilities and doubling its oncology pipeline.